Association between severe retinopathy of prematurity and nonvisual disabilities at age 5 years

JAMA

Volumn 311, Issue 5, 2014, Pages 523-525

  Schmidt, Barbara ^a   Davis, Peter G ^b   Asztalos, Elizabeth V ^c   Solimano, Alfonso ^d   Roberts, Robin S ^e  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HEARING IMPAIRMENT; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; PREMATURITY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RETINOPATHY; RISK FACTOR;

BLINDNESS; CASE-CONTROL STUDIES; CHILD, PRESCHOOL; COHORT STUDIES; DISABLED CHILDREN; FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; INTENSIVE CARE UNITS, NEONATAL; MALE; PROGNOSIS; RETINOPATHY OF PREMATURITY; RISK;

EID: 84893570967     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2013.282153     Document Type: Article

References (6)

1. Msall ME, Phelps DL, DiGaudio KM, et al; Behalf of the Cryotherapy for Retinopathy of Prematurity Cooperative Group. Severity of neonatal retinopathy of prematurity is predictive of neurodevelopmental functional outcome at age 5.5 years. Pediatrics. 2000;106(5):998-1005.
2. Schmidt B, Asztalos EV, Roberts RS, Robertson CM, Sauve RS, Whitfield MF; Trial of Indomethacin Prophylaxis in Preterms (TIPP) Investigators. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA. 2003;289(9):1124-1129. (Pubitemid 37430326)
3. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: natural history ROP: ocular outcome at 5(1/2) years in premature infants with birth weights less than 1251 g. Arch Ophthalmol. 2002;120(5):595-599.
4. Hintz SR, Kendrick DE, Vohr BR, Poole WK, Higgins RD; National Institute of Child Health and Human Development Neonatal Research Network. Changes in neurodevelopmental outcomes at 18 to 22 months' corrected age among infants of less than 25 weeks' gestational age born in 1993-1999. Pediatrics. 2005;115(6):1645-1651. (Pubitemid 43843175)
5. Doyle LW, Roberts G, Anderson PJ; Victorian Infant Collaborative Study Group. Changing long-term outcomes for infants 500-999 g birth weight in Victoria, 1979-2005. Arch Dis Child Fetal Neonatal Ed. 2011;96(6):F443-F447.
6. Schmidt B, Anderson PJ, Doyle LW, et al; Caffeine for Apnea of Prematurity (CAP) Trial Investigators. Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA. 2012;307(3):275-282.